Self-adaptive pyroptosis-responsive nanoliposomes block pyroptosis in autoimmune inflammatory diseases
© 2024 The Authors..
Nanoliposomes have a broad range of applications in the treatment of autoimmune inflammatory diseases because of their ability to considerably enhance drug transport. For their clinical application, nanoliposomes must be able to realize on-demand release of drugs at disease sites to maximize drug-delivery efficacy and minimize side effects. Therefore, responsive drug-release strategies for inflammation treatment have been explored; however, no specific design has been realized for a responsive drug-delivery system based on pyroptosis-related inflammation. Herein, we report a pioneering strategy for self-adaptive pyroptosis-responsive liposomes (R8-cardiolipin-containing nanoliposomes encapsulating dimethyl fumarate, RC-NLDMF) that precisely release encapsulated anti-pyroptotic drugs into pyroptotic cells. The activated key pyroptotic protein, the N-terminal domain of gasdermin E, selectively integrates with the cardiolipin of liposomes, thus forming pores for controlled drug release, pyroptosis, and inflammation inhibition. Therefore, RC-NL@DMF exhibited effective therapeutic efficacies to alleviate autoimmune inflammatory damages in zymosan-induced arthritis mice and dextran sulfate sodium-induced inflammatory bowel disease mice. Our novel approach holds great promise for self-adaptive pyroptosis-responsive on-demand drug delivery, suppressing pyroptosis and treating autoimmune inflammatory diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Bioactive materials - 36(2024) vom: 25. März, Seite 272-286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Kaiwang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-inflammation |
|---|
| Anmerkungen: |
Date Revised 19.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.bioactmat.2024.02.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369857240 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369857240 | ||
| 003 | DE-627 | ||
| 005 | 20240319233235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bioactmat.2024.02.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369857240 | ||
| 035 | |a (NLM)38496034 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Kaiwang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-adaptive pyroptosis-responsive nanoliposomes block pyroptosis in autoimmune inflammatory diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Nanoliposomes have a broad range of applications in the treatment of autoimmune inflammatory diseases because of their ability to considerably enhance drug transport. For their clinical application, nanoliposomes must be able to realize on-demand release of drugs at disease sites to maximize drug-delivery efficacy and minimize side effects. Therefore, responsive drug-release strategies for inflammation treatment have been explored; however, no specific design has been realized for a responsive drug-delivery system based on pyroptosis-related inflammation. Herein, we report a pioneering strategy for self-adaptive pyroptosis-responsive liposomes (R8-cardiolipin-containing nanoliposomes encapsulating dimethyl fumarate, RC-NLDMF) that precisely release encapsulated anti-pyroptotic drugs into pyroptotic cells. The activated key pyroptotic protein, the N-terminal domain of gasdermin E, selectively integrates with the cardiolipin of liposomes, thus forming pores for controlled drug release, pyroptosis, and inflammation inhibition. Therefore, RC-NL@DMF exhibited effective therapeutic efficacies to alleviate autoimmune inflammatory damages in zymosan-induced arthritis mice and dextran sulfate sodium-induced inflammatory bowel disease mice. Our novel approach holds great promise for self-adaptive pyroptosis-responsive on-demand drug delivery, suppressing pyroptosis and treating autoimmune inflammatory diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-inflammation | |
| 650 | 4 | |a Autoimmune inflammatory diseases | |
| 650 | 4 | |a Nanoliposome | |
| 650 | 4 | |a Pyroptosis | |
| 650 | 4 | |a Responsive drug delivery | |
| 700 | 1 | |a Yang, Huang |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Jinghua |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Kaijie |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Haotian |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Guanrui |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Qiangqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Canlong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Tengjing |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xinning |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiajie |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yunting |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Jiacheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Yuting |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Hongyun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Sunan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Siheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhuxing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Zhengwei |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Zongyou |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Xuesong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioactive materials |d 2016 |g 36(2024) vom: 25. März, Seite 272-286 |w (DE-627)NLM270377816 |x 2452-199X |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g day:25 |g month:03 |g pages:272-286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bioactmat.2024.02.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |b 25 |c 03 |h 272-286 | ||